Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02625480 · ClinicalTrials.gov registry record · Phase 1
Study Evaluating Brexucabtagene Autoleucel (KTE-X19) in Pediatric and Adolescent Participants With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia or Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
A Phase 1 study of Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma and Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia, sponsored by Kite, A Gilead Company.
- Active
- Registry status
- Phase 1
- Development phase
- 95
- Enrollment target
- 20
- Study locations
NCT02625480 is a Phase 1 study of Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma and Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia that is active but no longer recruiting, run by Kite, A Gilead Company. The registered enrollment target is 95 participants. The trial reports 20 study locations across 12 states.
The verdict
NCT02625480, a Phase 1 study of Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma and Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia, is active but no longer recruiting, sponsored by Kite, A Gilead Company.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 95 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary objectives of this study are to evaluate the safety and efficacy of brexucabtagene autoleucel (KTE-X19) in pediatric and adolescent participants with relapsed/refractory (r/r) B-precursor acute lymphoblastic leukemia (ALL) or relapsed or refractory (r/r) B-cell non-Hodgkin lymphoma (NHL). As of October 2022, no further patients with acute B-cell Acute Lymphoblastic Leukemia (ALL) will be asked to join the study. The study remains open for recruitment for patients that have B-cell Non Hodgkin Lymphoma (NHL).
Conditions Studied
Interventions
- DRUG Cyclophosphamide
- DRUG Fludarabine
- BIOLOGICAL Brexucabtagene Autoleucel (KTE-X19)
Study Locations (20)
Other
- University Hospital Gent - Ghent
- The Hospital for Sick Children - Toronto
- University Hospital Brno - Brno
- Unité d'Oncologie et Hématologie Pédiatriques - Bordeaux
- Institut d'Hematologie et Oncologie Pediatrique - Lyon
California
- Children's Hospital Los Angeles - Los Angeles
- Children's Hospital of Orange County - Orange
- UCSF Benioff Children's Hospital - San Francisco
New York
- Columbia University Irving Medical Center/Morgan Stanley Children's Hospital-NYP - New York
- University of Rochester Medical Center - Rochester
Texas
- Texas Children's Hospital - Houston
- The University of Texas M.D. Anderson Cancer Center - Houston
Florida
- University of Miami Hospital & Clinics - Miami
Hawaii
- Kapi'olani Medical Center for Women and Children - Honolulu
Illinois
- Ann & Robert H. Lurie Children's Hospital - Chicago
Maryland
- Johns Hopkins University - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 95 participants |
| Start Date | 2016-02-01 |
| Est. Completion | 2026-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02625480
The ClinicalTrials.gov registry entry for NCT02625480 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 95 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kite, A Gilead Company, which has 28 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma appearing as the primary indexed condition, and to 3 interventions - of which Cyclophosphamide is the first listed.
NCT02625480 reports 20 study locations spanning 12 distinct geographic areas - top geographies include Other, California, New York.
Frequently Asked Questions
What is clinical trial NCT02625480 about?
NCT02625480 is a clinical study titled "Study Evaluating Brexucabtagene Autoleucel (KTE-X19) in Pediatric and Adolescent Participants With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia or Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma". The primary objectives of this study are to evaluate the safety and efficacy of brexucabtagene autoleucel (KTE-X19) in pediatric and adolescent participants with relapsed/refractory (r/r) B-precursor acute lymphoblastic leukemia (ALL) or relapsed or refractory (r/r) B-cell non-Hodgkin lymphoma (NHL)...
What is the current status of trial NCT02625480?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 95 participants. The study started on 2016-02-01. Estimated completion is 2026-02.
What conditions does trial NCT02625480 study?
This clinical trial studies the following conditions: Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma, Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia.
What interventions are being tested in trial NCT02625480?
The interventions under investigation include: Cyclophosphamide (DRUG), Fludarabine (DRUG), Brexucabtagene Autoleucel (KTE-X19) (BIOLOGICAL).
Who is sponsoring clinical trial NCT02625480?
This trial is sponsored by Kite, A Gilead Company, which has 28 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02625480 being conducted?
This trial has 20 study locations across California, Florida, Hawaii, Illinois, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
All registered trials for this condition
Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia
All registered trials for this condition
California
All trials with a study site in California
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.